Department of Respiratory Medicine, Toho University Omori Medical Center, 6-11-1 Omori-nishi, Ota-ku, Tokyo 143-8541, Japan.
Int J Clin Oncol. 2009 Dec;14(6):497-501. doi: 10.1007/s10147-009-0905-4. Epub 2009 Dec 5.
Positron emission tomography with 18-fluorodeoxyglucose (FDG-PET) has been useful for the detection of recurrent lung cancer. However, such technology is expensive and is not always widely available. In this study, we evaluated the selected use of FDG-PET for lung cancer patients with re-elevated levels of serum carcinoembryonic antigen (CEA) after curative surgery.
Among 327 patients who underwent curative resection for primary lung cancer from May 2002 through March 2007, 199 had adenocarcinoma, of whom 78 (39%) had elevated levels of serum CEA before treatment. After surgery, the level was monitored every 1 to 3 months. Re-elevation of CEA was recognized in 39 (50%) patients, 22 of whom underwent FDG-PET and were included in this study. FDG-PET images were visually inspected, and abnormally increased FDG uptake was interpreted as recurrence. The sensitivity, specificity, positive predictive value, and negative predictive value of PET in detecting recurrent lung cancer were determined.
FDG-PET correctly identified 14 out of 15 relapses and gave true negative results in six out of seven remissions, i.e., one false-negative and one false-positive were observed. The sensitivity, specificity, positive predictive value, and negative predictive value were 93%, 86%, 93%, and 86%, respectively.
In 64% of the patients with unexplained increased CEA levels, FDG-PET provided decisive diagnostic clues guiding further diagnostic and therapeutic interventions. The selected use of FDG-PET for patients with re-elevated serum CEA levels after surgery can be a practical and effective mode of surveillance for detecting recurrent lung cancer.
正电子发射断层扫描(PET)与 18-氟脱氧葡萄糖(FDG-PET)结合,有助于发现复发性肺癌。然而,这种技术价格昂贵,且并非广泛可用。在本研究中,我们评估了 FDG-PET 在根治性手术后癌胚抗原(CEA)水平升高的肺癌患者中的选择性应用。
在 2002 年 5 月至 2007 年 3 月期间接受根治性手术的 327 例原发性肺癌患者中,有 199 例为腺癌,其中 78 例(39%)在治疗前 CEA 水平升高。手术后,每 1-3 个月监测一次。39 例(50%)患者的 CEA 再次升高,其中 22 例行 FDG-PET 检查,并纳入本研究。通过肉眼观察 FDG-PET 图像,将 FDG 摄取异常增加解读为复发。确定 FDG-PET 检测复发性肺癌的敏感性、特异性、阳性预测值和阴性预测值。
FDG-PET 正确识别了 15 例复发中的 14 例,在 7 例缓解中的 6 例中给出了真正的阴性结果,即观察到 1 例假阴性和 1 例假阳性。敏感性、特异性、阳性预测值和阴性预测值分别为 93%、86%、93%和 86%。
在 64%CEA 水平升高但原因不明的患者中,FDG-PET 提供了决定性的诊断线索,指导进一步的诊断和治疗干预。在根治性手术后 CEA 水平升高的患者中,选择性使用 FDG-PET 可以作为检测复发性肺癌的一种实用、有效的监测方法。